Publications by authors named "Ningping Xiao"
Background: The LUNAR trial demonstrated the significant efficacy and safety of Tumor Treating Fields (TTFields) plus standard-of-care (SOC) [immune checkpoint inhibitor (ICI) and docetaxel (DTX)] for patients with previously treated metastatic non-small cell lung cancer (mNSCLC). However, it remains uncertain as to whether the high costs are justified by the corresponding survival benefits. Here, the cost-effectiveness of using TTFields plus SOC for treating mNSCLC was evaluated from the perspective of the Chinese healthcare system.
View Article and Find Full Text PDFArticle Synopsis
- The RATIONALE-309 trial confirmed that a combination of tislelizumab and chemotherapy is both effective and safe for patients with recurrent or metastatic nasopharyngeal carcinoma.
- The study found that adding tislelizumab to chemotherapy increases treatment costs by $17,711 but provides an additional 1.05 Quality-Adjusted Life Years (QALYs), resulting in a cost-effectiveness ratio (ICER) of $16,859/QALY, which is below the willingness-to-pay threshold of $36,289/QALY.
- Sensitivity and subgroup analyses indicated that the combination treatment is cost-effective across different patient groups, making tislelizumab plus chemotherapy a viable option for R/M NPC treatment in